These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8787036)

  • 21. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate.
    Jann MW; Wei FC; Lin HN; Piao-Chien C; Chang WH
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 Jan; 20(1):73-86. PubMed ID: 8861178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
    Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
    J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of haloperidol decanoate on plasma homovanillic acid in chronic schizophrenic patients.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Lane HY; Jann MW
    Biol Psychiatry; 1993 Apr; 33(7):557-9. PubMed ID: 8513043
    [No Abstract]   [Full Text] [Related]  

  • 25. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN; Korpi ER; Kirch DG
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting haloperidol treatment response in chronic schizophrenia.
    van Kammen DP; Kelley ME; Yao JK; Gilbertson MW; Gurklis JA; Inosaka T; Saito H; Peters JL; Sato M
    Psychiatry Res; 1996 Aug; 64(1):47-58. PubMed ID: 8888364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.
    Young D; Midha KK; Fossler MJ; Hawes EM; Hubbard JW; McKay G; Korchinski ED
    Eur J Clin Pharmacol; 1993; 44(5):433-8. PubMed ID: 8359179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
    Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
    J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics.
    Kim YK; Kim L; Lee MS
    Schizophr Res; 2000 Sep; 44(3):165-75. PubMed ID: 10962218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment plasma HVA and haloperidol response in acute mania.
    Chou JC; Czobor P; Tuma I; Charles O; Bebe R; Cooper TB; Chang WH; Lane HY; Stone DL
    J Affect Disord; 2000 Jul; 59(1):55-9. PubMed ID: 10814771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The plasma levels of haloperidol and reduced haloperidol in Japanese psychiatric patients].
    Someya T; Shibasaki M; Takahashi S
    Yakubutsu Seishin Kodo; 1989 Jun; 9(2):207-15. PubMed ID: 2816093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors affecting the clinical response to haloperidol therapy in schizophrenia.
    Bareggi SR; Mauri M; Cavallaro R; Regazzetti MG; Moro AR
    Clin Neuropharmacol; 1990; 13 Suppl 1():S29-34. PubMed ID: 2379182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population.
    Someya T; Shimoda K; Suzuki Y; Sato S; Kawashima Y; Hirokane G; Morita S; Yokono A; Takahashi S
    Neuropsychopharmacology; 2003 Aug; 28(8):1501-5. PubMed ID: 12784098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.
    Smith RC; Baumgartner R; Shvartsburd A; Ravichandran GK; Vroulis G; Mauldin M
    Psychopharmacology (Berl); 1985; 85(4):449-55. PubMed ID: 2862652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.
    Vasavan Nair NP; Suranyi-Cadotte B; Schwartz G; Thavundayil JX; Achim A; Lizondo E; Nayak R
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):30S-37S. PubMed ID: 3514689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interconversion between haloperidol and reduced haloperidol in healthy volunteers.
    Chakraborty BS; Hubbard JW; Hawes EM; McKay G; Cooper JK; Gurnsey T; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1989; 37(1):45-8. PubMed ID: 2591462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement of haloperidol reductase activity in red blood cells and reduced haloperidol/haloperidol ratios in plasma in oriental psychiatric patients.
    Shibasaki M; Someya T; Kato T; Noguchi T; Ishida N; Takahashi S
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):941-7. PubMed ID: 2277853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.